DBV Technologies submits BLA to U.S. FDA for Viaskin peanut patch in children aged 4-7

DBV Technologies SA said it submitted a Biologics License Application to the U.S. FDA for its Viaskin® peanut patch in children aged 4-7, requesting priority review.